TECH
Bio-Techne
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 4
Sell signal 1
ample liquidity
High Gross Profit Margin
Upward Gap
High Cash/net Profit Ratio
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About TECH
Bio-Techne Corporation
A leading developer and manufacturer of biotechnology reagents and instruments for research, diagnostics, and pharmaceutical applications
Life Science Tools and Services
07/17/1981
05/12/1989
NASDAQ Stock Exchange
3100
06-30
Common stock
614 McKinley Place N.E., Minneapolis, MN 55413
--
Bio-Techne Corporation was founded in Minnesota on July 17, 1981. Bio-Techne and its subsidiaries jointly operate businesses that develop, manufacture and sell life science reagents, instruments and services for the global research, diagnostic and bioprocessing markets. With its deep product portfolio and applied expertise, the company sells components of scientific investigations of biological processes and molecular diagnosis, revealing the nature, diagnosis, etiology and progression of specific diseases.
Company Financials
EPS
TECH has released its 2025 Q2 earnings. EPS was reported at 0.42, versus the expected 0.38, beating expectations. The chart below visualizes how TECH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TECH has released its 2025 Q2 earnings report, with revenue of 297.03M, reflecting a YoY change of 8.96%, and net profit of 34.89M, showing a YoY change of 27.03%. The Sankey diagram below clearly presents TECH’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
